Hamlet Gasoyan

20PUBLICATIONS
20CO-AUTHORS
Toxicology (incl. clinical toxicology)Predictive and prognostic markersBehavioural epidemiologyMetabolic medicinePharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Jul 08, 2026
Comparing benefits and harms of obesity drugs.

|May 18, 2026
Triplet or Quadruplet Regimen Utilization and Overall Survival in Patients Diagnosed With Multiple Myeloma Between 2017 and 2023.

|Mar 12, 2026
Obesity Treatments and Weight Changes in Clinical Practice After Discontinuation of Semaglutide or Tirzepatide.

Hamlet Gasoyan, Rebecca Schulte, Christopher B Boyer

|Feb 25, 2026
Trends in Use of Obesity Medications and Metabolic and Bariatric Surgery Among All of Us Participants From 2003 to 2023.

Olajide A Adekunle, Phuc Le, Christopher Boyer

|Oct 03, 2025
Reasons for Discontinuation of Obesity Pharmacotherapy With Semaglutide or Tirzepatide in Clinical Practice.

Hamlet Gasoyan, W Scott Butsch, Nicholas J Casacchia

|Sep 16, 2025
Macrovascular and microvascular outcomes of metabolic surgery versus GLP-1 receptor agonists in patients with diabetes and obesity.

Hamlet Gasoyan, Mohammad Hesam Alavi, Alexander Zajichek

Pageof 4

Frequent Collaborators

3 joint publications

Nicholas J Casacchia

2 joint publications

Faiz Anwer

2 joint publications

Michael T Halpern

2 joint publications

Ali Aminian